EUVIMEDEUVIMED entdecken
Systematische Übersicht

Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations

Josephine Aikpitanyi, Florence Pierrard, Catherine Pétein, Perrine Evrard, Anne Spinewine, Sandy Tubeuf

Applied Health Economics and Health Policy · 2026-09 · 24 (5) · 825-840

DOI: 10.1007/s40258-026-01052-4 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Applied Health Economics and Health Policy, online erschienen am 15.06.2026. Verfasst von Josephine Aikpitanyi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health and Society Research (IRSS), Faculty of Public Health, Université catholique de Louvain, Brussels, Belgium. josephine.aikpitanyi@…. Hauptthemen laut MEDLINE: Deprescriptions, Polypharmacy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Actions de Recherche Concertées Communauté Française Belgique.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Deprescribing is increasingly promoted to address polypharmacy and medication-related harm in older adults. However, its economic value as a distinct intervention remains unclear, as prior reviews have often conflated deprescribing with broader medication optimisation strategies. This systematic review synthesises the economic evidence on deprescribing using a strict conceptual definition.

Methods

A systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted from January 2000 to June 2025. Studies were included if they reported full economic evaluations (cost-effectiveness, cost-utility, cost-benefit, or cost-consequence analyses) of interventions explicitly involving medication discontinuation in adults aged ≥ 65 years. The methodological quality of included studies was assessed using the Consensus on Health Economic Criteria (CHEC) checklist, and reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 statement. Cost data were standardised to 2024 US dollars using purchasing power parity where feasible.

Results

Eight studies were included (two trial-based, six model-based). Deprescribing interventions targeting medications with well-established harm profiles, such as sedatives, non-steroidal anti-inflammatory drugs, and proton pump inhibitors (prolonged use), were most consistently cost-saving or dominant, primarily through reductions in adverse drug events. In contrast, evidence for antihypertensive deprescribing was limited and context dependent, with one model-based study suggesting potential long-term harms under specific assumptions. Across studies, economic outcomes were strongly influenced by intervention design and implementation, with structured, multi-component approaches demonstrating greater effectiveness. Quality assessment indicated generally robust methodological foundations but identified gaps in the handling of uncertainty, transparency in reporting, and the inclusion of broader cost components.

Conclusion

Deprescribing can represent good value for money when targeted to high-risk medications and supported by structured implementation strategies. Its economic value is not universal but depends on patient context, medication class, and intervention design. Future research should prioritise methodologically rigorous, transparent, and context-sensitive economic evaluations to inform policy and practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeprescriptionsPolypharmacyHumansCost-Benefit AnalysisAgedCost-Effectiveness Analysis

Autor:innen und Institutionen

  • Institute of Health and Society Research (IRSS), Faculty of Public Health, Université catholique de Louvain, Brussels, Belgium. josephine.aikpitanyi@uclouvain.be.
  • Institute of Health and Society Research (IRSS), Faculty of Public Health, Université catholique de Louvain, Brussels, Belgium.
  • Clinical Pharmacy and Pharmacoepidemiology Research Group, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium.
  • Pharmacy Department, CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium.

Förderung

  • Actions de Recherche Concertées Communauté Française Belgique

Zitieren

APA

Aikpitanyi, J., Pierrard, F., Pétein, C., Evrard, P., Spinewine, A., & Tubeuf, S. (2026). Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations. Applied Health Economics and Health Policy, 24(5), 825-840. https://doi.org/10.1007/s40258-026-01052-4

Vancouver

Aikpitanyi J, Pierrard F, Pétein C, Evrard P, Spinewine A, Tubeuf S. Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations. Applied Health Economics and Health Policy. 2026;24(5):825-840. doi:10.1007/s40258-026-01052-4

BibTeX
@article{Aikpitanyi2026,
  author = {Aikpitanyi, Josephine and Pierrard, Florence and Pétein, Catherine and Evrard, Perrine and Spinewine, Anne and Tubeuf, Sandy},
  title = {Deprescribing Interventions in Older Adults with Polypharmacy: A Systematic Review of Economic Evaluations},
  journal = {Applied Health Economics and Health Policy},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {825--840},
  doi = {10.1007/s40258-026-01052-4}
}
Kostenlos starten →